Pacira BioSciences (PCRX) Short term Debt (2010 - 2025)

Pacira BioSciences' Short term Debt history runs 14 years deep, the most recent figure standing at $202.4 million for Q2 2025.

• In Q2 2025, Short term Debt changed N/A year-over-year to $202.4 million; the TTM figure through Jun 2025 stood at $202.4 million (changed N/A YoY), while the FY2024 annual figure was $201.8 million, up 2235.1% from the prior year.
• Short term Debt was $202.4 million for Q2 2025 at Pacira BioSciences, roughly flat from $202.1 million in the prior quarter.
• In the past five years, Short term Debt ranged from a high of $350.5 million in Q4 2021 to a low of $8.6 million in Q4 2023.
• Historically, Short term Debt has averaged $117.3 million across 5 years, with a median of $151.6 million in 2021.
• The sharpest annual moves came in 2022 and 2025: Short term Debt slumped 90.4% in 2022, then soared 2238.69% in 2025.
• A 5-year view of Short term Debt shows it stood at $350.5 million in 2021, then plunged by 90.4% to $33.6 million in 2022, then sank by 74.32% to $8.6 million in 2023, then soared by 2235.1% to $201.8 million in 2024, then grew by 0.31% to $202.4 million in 2025.
• The last three Short term Debt figures came in at $202.4 million (Q2 2025), $202.1 million (Q1 2025), and $201.8 million (Q4 2024), per Business Quant data.